Selected research
Industry Research
Chronic Rhinosinusitis With Nasal Polyps Industry Research Report 2026
Market perspective
The global Chronic Rhinosinusitis With Nasal Polyps market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Chronic Rhinosinusitis With Nasal Polyps is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Chronic Rhinosinusitis With Nasal Polyps is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Chronic Rhinosinusitis With Nasal Polyps is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Chronic Rhinosinusitis With Nasal Polyps include Teva, Sanofi, Novartis, GSK, Wockhardt, West-Ward Pharmaceuticals, Regeneron, Optinose and Genentech, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Chronic Rhinosinusitis With Nasal Polyps market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Chronic Rhinosinusitis With Nasal Polyps Market by Company
Teva
Sanofi
Novartis
GSK
Wockhardt
West-Ward Pharmaceuticals
Regeneron
Optinose
Genentech
AstraZeneca
Apotex Corp.
Akorn
Chronic Rhinosinusitis With Nasal Polyps Segment by Type
Anti-leukotriene drugs
Antihistamines
Biologics
Glucocorticoids
Other
Chronic Rhinosinusitis With Nasal Polyps Segment by Application
Hospital
Clinic
Other
Chronic Rhinosinusitis With Nasal Polyps Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Chronic Rhinosinusitis With Nasal Polyps market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Chronic Rhinosinusitis With Nasal Polyps and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Chronic Rhinosinusitis With Nasal Polyps.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Chronic Rhinosinusitis With Nasal Polyps manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Chronic Rhinosinusitis With Nasal Polyps by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Chronic Rhinosinusitis With Nasal Polyps in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Anti-leukotriene drugs
- Antihistamines
- Biologics
- Glucocorticoids
- Other
Applications
- Hospital
- Clinic
- Other
Companies covered
- Teva
- Sanofi
- Novartis
- GSK
- Wockhardt
- West-Ward Pharmaceuticals
- Regeneron
- Optinose
- Genentech
- AstraZeneca
- Apotex Corp.
- Akorn
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Chronic Rhinosinusitis With Nasal Polyps Market Size (2021-2032)
- 2.2.2 Global Chronic Rhinosinusitis With Nasal Polyps Sales (2021-2032)
- 2.2.3 Global Chronic Rhinosinusitis With Nasal Polyps Market Average Price (2021-2032)
- 2.3 Chronic Rhinosinusitis With Nasal Polyps by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Anti-leukotriene drugs
- 2.3.3 Antihistamines
- 2.3.4 Biologics
- 2.3.5 Glucocorticoids
- 2.3.6 Other
- 2.4 Chronic Rhinosinusitis With Nasal Polyps by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Hospital
- 2.4.3 Clinic
- 2.4.4 Other
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Chronic Rhinosinusitis With Nasal Polyps Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Chronic Rhinosinusitis With Nasal Polyps Sales (K Units) of Manufacturers (2021-2026)
- 3.3 Global Chronic Rhinosinusitis With Nasal Polyps Revenue of Manufacturers (2021-2026)
- 3.4 Global Chronic Rhinosinusitis With Nasal Polyps Average Price by Manufacturers (2021-2026)
- 3.5 Global Chronic Rhinosinusitis With Nasal Polyps Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Chronic Rhinosinusitis With Nasal Polyps, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Chronic Rhinosinusitis With Nasal Polyps, Product Type & Application
- 3.8 Global Manufacturers of Chronic Rhinosinusitis With Nasal Polyps, Established Date
- 3.9 Global Chronic Rhinosinusitis With Nasal Polyps Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Teva
- 4.1.1 Teva Company Information
- 4.1.2 Teva Business Overview
- 4.1.3 Teva Chronic Rhinosinusitis With Nasal Polyps Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Teva Chronic Rhinosinusitis With Nasal Polyps Product Portfolio
- 4.1.5 Teva Recent Developments
- 4.2 Sanofi
- 4.2.1 Sanofi Company Information
- 4.2.2 Sanofi Business Overview
- 4.2.3 Sanofi Chronic Rhinosinusitis With Nasal Polyps Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Sanofi Chronic Rhinosinusitis With Nasal Polyps Product Portfolio
- 4.2.5 Sanofi Recent Developments
- 4.3 Novartis
- 4.3.1 Novartis Company Information
- 4.3.2 Novartis Business Overview
- 4.3.3 Novartis Chronic Rhinosinusitis With Nasal Polyps Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Novartis Chronic Rhinosinusitis With Nasal Polyps Product Portfolio
- 4.3.5 Novartis Recent Developments
- 4.4 GSK
- 4.4.1 GSK Company Information
- 4.4.2 GSK Business Overview
- 4.4.3 GSK Chronic Rhinosinusitis With Nasal Polyps Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 GSK Chronic Rhinosinusitis With Nasal Polyps Product Portfolio
- 4.4.5 GSK Recent Developments
- 4.5 Wockhardt
- 4.5.1 Wockhardt Company Information
- 4.5.2 Wockhardt Business Overview
- 4.5.3 Wockhardt Chronic Rhinosinusitis With Nasal Polyps Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Wockhardt Chronic Rhinosinusitis With Nasal Polyps Product Portfolio
- 4.5.5 Wockhardt Recent Developments
- 4.6 West-Ward Pharmaceuticals
- 4.6.1 West-Ward Pharmaceuticals Company Information
- 4.6.2 West-Ward Pharmaceuticals Business Overview
- 4.6.3 West-Ward Pharmaceuticals Chronic Rhinosinusitis With Nasal Polyps Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 West-Ward Pharmaceuticals Chronic Rhinosinusitis With Nasal Polyps Product Portfolio
- 4.6.5 West-Ward Pharmaceuticals Recent Developments
- 4.7 Regeneron
- 4.7.1 Regeneron Company Information
- 4.7.2 Regeneron Business Overview
- 4.7.3 Regeneron Chronic Rhinosinusitis With Nasal Polyps Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Regeneron Chronic Rhinosinusitis With Nasal Polyps Product Portfolio
- 4.7.5 Regeneron Recent Developments
- 4.8 Optinose
- 4.8.1 Optinose Company Information
- 4.8.2 Optinose Business Overview
- 4.8.3 Optinose Chronic Rhinosinusitis With Nasal Polyps Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Optinose Chronic Rhinosinusitis With Nasal Polyps Product Portfolio
- 4.8.5 Optinose Recent Developments
- 4.9 Genentech
- 4.9.1 Genentech Company Information
- 4.9.2 Genentech Business Overview
- 4.9.3 Genentech Chronic Rhinosinusitis With Nasal Polyps Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Genentech Chronic Rhinosinusitis With Nasal Polyps Product Portfolio
- 4.9.5 Genentech Recent Developments
- 4.10 AstraZeneca
- 4.10.1 AstraZeneca Company Information
- 4.10.2 AstraZeneca Business Overview
- 4.10.3 AstraZeneca Chronic Rhinosinusitis With Nasal Polyps Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 AstraZeneca Chronic Rhinosinusitis With Nasal Polyps Product Portfolio
- 4.10.5 AstraZeneca Recent Developments
- 4.11 Apotex Corp.
- 4.11.1 Apotex Corp. Company Information
- 4.11.2 Apotex Corp. Business Overview
- 4.11.3 Apotex Corp. Chronic Rhinosinusitis With Nasal Polyps Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Apotex Corp. Chronic Rhinosinusitis With Nasal Polyps Product Portfolio
- 4.11.5 Apotex Corp. Recent Developments
- 4.12 Akorn
- 4.12.1 Akorn Company Information
- 4.12.2 Akorn Business Overview
- 4.12.3 Akorn Chronic Rhinosinusitis With Nasal Polyps Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 Akorn Chronic Rhinosinusitis With Nasal Polyps Product Portfolio
- 4.12.5 Akorn Recent Developments
5 Global Chronic Rhinosinusitis With Nasal Polyps Market Scenario by Region
- 5.1 Global Chronic Rhinosinusitis With Nasal Polyps Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Chronic Rhinosinusitis With Nasal Polyps Sales by Region: 2021-2032
- 5.2.1 Global Chronic Rhinosinusitis With Nasal Polyps Sales by Region: 2021-2026
- 5.2.2 Global Chronic Rhinosinusitis With Nasal Polyps Sales by Region: 2027-2032
- 5.3 Global Chronic Rhinosinusitis With Nasal Polyps Revenue by Region: 2021-2032
- 5.3.1 Global Chronic Rhinosinusitis With Nasal Polyps Revenue by Region: 2021-2026
- 5.3.2 Global Chronic Rhinosinusitis With Nasal Polyps Revenue by Region: 2027-2032
- 5.4 North America Chronic Rhinosinusitis With Nasal Polyps Market Facts & Figures by Country
- 5.4.1 North America Chronic Rhinosinusitis With Nasal Polyps Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Chronic Rhinosinusitis With Nasal Polyps Sales by Country (2021-2032)
- 5.4.3 North America Chronic Rhinosinusitis With Nasal Polyps Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Chronic Rhinosinusitis With Nasal Polyps Market Facts & Figures by Country
- 5.5.1 Europe Chronic Rhinosinusitis With Nasal Polyps Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Chronic Rhinosinusitis With Nasal Polyps Sales by Country (2021-2032)
- 5.5.3 Europe Chronic Rhinosinusitis With Nasal Polyps Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Chronic Rhinosinusitis With Nasal Polyps Market Facts & Figures by Country
- 5.6.1 Asia Pacific Chronic Rhinosinusitis With Nasal Polyps Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Chronic Rhinosinusitis With Nasal Polyps Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Chronic Rhinosinusitis With Nasal Polyps Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Chronic Rhinosinusitis With Nasal Polyps Market Facts & Figures by Country
- 5.7.1 South America Chronic Rhinosinusitis With Nasal Polyps Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Chronic Rhinosinusitis With Nasal Polyps Sales by Country (2021-2032)
- 5.7.3 South America Chronic Rhinosinusitis With Nasal Polyps Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Chronic Rhinosinusitis With Nasal Polyps Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Chronic Rhinosinusitis With Nasal Polyps Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Chronic Rhinosinusitis With Nasal Polyps Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Chronic Rhinosinusitis With Nasal Polyps Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Chronic Rhinosinusitis With Nasal Polyps Sales by Type (2021-2032)
- 6.1.1 Global Chronic Rhinosinusitis With Nasal Polyps Sales by Type (2021-2032) & (K Units)
- 6.1.2 Global Chronic Rhinosinusitis With Nasal Polyps Sales Market Share by Type (2021-2032)
- 6.2 Global Chronic Rhinosinusitis With Nasal Polyps Revenue by Type (2021-2032)
- 6.2.1 Global Chronic Rhinosinusitis With Nasal Polyps Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Chronic Rhinosinusitis With Nasal Polyps Revenue Market Share by Type (2021-2032)
- 6.3 Global Chronic Rhinosinusitis With Nasal Polyps Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Chronic Rhinosinusitis With Nasal Polyps Sales by Application (2021-2032)
- 7.1.1 Global Chronic Rhinosinusitis With Nasal Polyps Sales by Application (2021-2032) & (K Units)
- 7.1.2 Global Chronic Rhinosinusitis With Nasal Polyps Sales Market Share by Application (2021-2032)
- 7.2 Global Chronic Rhinosinusitis With Nasal Polyps Revenue by Application (2021-2032)
- 7.2.1 Global Chronic Rhinosinusitis With Nasal Polyps Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Chronic Rhinosinusitis With Nasal Polyps Revenue Market Share by Application (2021-2032)
- 7.3 Global Chronic Rhinosinusitis With Nasal Polyps Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Chronic Rhinosinusitis With Nasal Polyps Value Chain Analysis
- 8.1.1 Chronic Rhinosinusitis With Nasal Polyps Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Chronic Rhinosinusitis With Nasal Polyps Production Mode & Process
- 8.2 Chronic Rhinosinusitis With Nasal Polyps Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Chronic Rhinosinusitis With Nasal Polyps Distributors
- 8.2.3 Chronic Rhinosinusitis With Nasal Polyps Customers
9 Global Chronic Rhinosinusitis With Nasal Polyps Analyzing Market Dynamics
- 9.1 Chronic Rhinosinusitis With Nasal Polyps Industry Trends
- 9.2 Chronic Rhinosinusitis With Nasal Polyps Industry Drivers
- 9.3 Chronic Rhinosinusitis With Nasal Polyps Industry Opportunities and Challenges
- 9.4 Chronic Rhinosinusitis With Nasal Polyps Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst